No. pts Age (years) Gender CLL stage Hb ×109/L WBC ×109/L Plt ×109/L FORDvalues (mmol/L) FORTvalues (mmol/L) Survival (years)
1. 58 M A 11.9 23.1 252 0.98 2.8 7.8
2. 72 M C 10.3 40.9 102 0.62 3.1 3.1
3 63 M B 12.1 54.9 368 0.73 3.0 6.1
4. 67 M C 10.9 31.8 74 0.39 2.9 6.6
5. 51 M B 12.8 65.6 343 0.84 2.6 8.2
6. 79 F B 11.4 29.7 322 0.59 3.3 5.3
7. 66 F A 12.2 33.8 245 0.57 2.7 9.2
8. 64 F A 12.4 36.2 336 0.86 2.4 14.6
9. 81 M B 12.0 41.8 265 0.94 3.6 3.2
10. 49 M B 12.3 48.4 373 0.82 3.4 7.9
11. 62 F A 11.6 25.3 381 1.02 2.5 12.2
12. 68 F C 10.9 38.2 104 0.67 3.2 5.5
13. 59 F B 11.4 45.8 264 0.56 2.7 6.8
14 71 M B 11.6 57.5 364 0.83 3.6 4.5
15. 68 M C 11.0 36.6 98 0.56 2.7 4.8
16 62 M A 12.3 27.9 372 0.85 2.5 12.1
17. 73 F C 9.7 49.3 80 0.41 3.3 2.9
18. 57 M B 12.6 48.9 298 0.84 3.6 6.8
19. 69 F C 10.8 53.1 92 0.71 3.8 5.9
20. 61 M B 12.5 57.3 274 0.62 3.4 4.6
21. 74 M C 9.6 44.2 104 0.54 2.6 2.8
22. 56 M B 12,4 46.9 365 0.86 3.8 5.6
23. 72 F C 9.4 43.1 88 0.66 3.1 2.5
24. 58 M B 12.7 44.6 382 0.92 3.4 6.9
25. 66 M C 8.0 30.2 68 0.84 3.5 6.9
26. 64 M A 12.0 36.2 363 0.56 2.8 10.3
27. 70 M C 10.4 46.0 94 0.58 2.9 3.4
28 60 F A 12.2 29.8 366 0.98 2.4 14.2
29. 47 M B 12.4 56.9 343 0.64 2.9 6.5
30. 83 M A 12.1 38.3 274 0.46 3.7 3.4
31. 70 M C 10.8 65.3 80 0.49 3.1 4.5
32. 59 F B 11.9 37.9 246 0.69 3.4 6.8
33. 63 F A 12.3 27.0 386 0.87 3.1 8.2
34. 68 F B 11.4 43.7 342 0.83 3.7 4.9
35. 74 M C 9.2 47.1 114 0.55 2.5 2,7
36. 56 F A 11.8 29.2 394 0.56 2.4 19.1
37. 56 M A 12.4 34.6 383 0.77 2.7 11.1
38 74 M C 10.6 67.2 78 0.72 3.4 2.8
39. 51 F B 11.8 41.3 374 0.84 3.8 4.6
40. 79 M B 11.9 58.5 376 0.52 3.8 3.6
41. 68 M A 12.0 33.4 342 0.76 3.2 9.3
42. 62 F B 11.6 48.5 283 0.99 3.6 5.8
43. 71 F C 10.4 43.0 103 0.96 2.6 2.5
44. 59 M B 11.6 54.0 352 0.87 2.8 7.8
45. 73 M C 9.6 44.1 96 0.52 3.2 2.4
46. 57 M B 11.8 48.3 294 0.78 3.5 5.6
47. 77 M C 10.8 60.2 84 0.81 3.4 2.2
48. 53 F A 11.5 29.4 384 1.01 2.6 7
49. 69 M C 10.0 46.1 112 0.75 2.8 3.1
50. 61 F A 11.6 27.8 343 0.98 2.5 11.2
51. 53 M B 12,1 78.3 274 0.94 3.6 6.8
52. 77 F A 11.4 45.6 232 0.65 3.2 5.4
53. 64 F A 11.7 33.4 345 0.78 2.4 13.1
54 66 F C 9.5 50.2 78 0.84 2.9 3.2
55. 50 M B 11.6 43.6 236 0.89 3.0 6.9
56. 80 M C 10.3 48.9 94 0.74 3.4 2.1
57. 55 M B 11.9 37.8 324 0.98 3.8 4.6
58. 75 M C 10.0 41.2 88 0.66 2.8 2.8
59. 61 F B 11.2 43.6 245 0.48 3.5 5.9
60. 64 M A 11.9 56.0 324 0.78 2.6 10.2
61. 69 F C 9.8 40.1 72 0.82 3.2 3.5
62. 66 M B 11.2 47.6 263 0.56 3.6 4.5
63. 73 M C 10.2 30.1 91 0.72 3.0 2.3
64. 57 M B 12.6 47.3 326 0.75 3.5 5.3
65. 76 M C 9,7 53.2 79 0.68 3.3 2.6
66. 54 M A 12.5 25.7 394 0.66 2.4 17
67. 70 M C 10.5 37.0 93 0.56 2.9 3.3
68. 61 F A 11.4 28.9 325 1.02 2.8 12.2
69. 69 F B 12.1 34.9 348 0.88 3.4 6.1
70. 60 M B 12.2 49.3 347 0.96 3.3 6.3
71. 72 M C 10.1 45.1 91 0.78 2.6 2.8
72. 58 F A 11.9 34.2 324 1.02 2.4 17
73. 56 M B 12.4 48.9 353 0.78 2.9 5.1
74. 74 F C 9.4 48.4 89 0.56 3.0 2.1
75. 75 M C 10.9 44.8 104 0.52 2.9 2.6
76. 55 M B 12.4 46.6 348 0.65 3.4 6.1
77. 70 M C 10.6 40.2 106 0.54 3.1 3.1
78. 62 F A 12.2 28.4 325 0.76 3.2 5.4
79 60 F A 11.9 34.6 389 0,98 2.6 11.4
80 68 F C 9.9 45.3 82 0.82 3.3 3.5
81. 78 M C 10.0 45.4 85 0.57 3.2 2.7
82. 52 M B 12.4 34.9 354 0.78 3.6 5.3
83. 57 F A 11.8 26.9 389 0.99 2.6 10.8
84 73 M C 9.1 45.8 78 0.48 2.8 2.9
Table 1: Characteristics of patients with CLL.